Share ownership Sarepta Therapeutics, Inc.

SRPT

US8036071004

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 02:30:00 14/02/2026 am IST			5-day change	1st Jan Change
17.79 ^USD	+2.24%		-3.84%	-17.33%

11/02	Sarepta Therapeutics to announce fourth quarter and full-year 2025 financial results	RE
04/02	Sarepta Therapeutics announces clinical trial application approval for SRP-1005 in Huntington's disease	RE

Share class: Sarepta Therapeutics, Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	9,55,19,650	9,13,46,261 ( 95.63 %)	0	95.63 %

Major shareholders: Sarepta Therapeutics, Inc.

Name	Equities	%	Valuation
BlackRock Advisors LLC 12.73 %	1,33,35,203	12.73 %	271 M $
Vanguard Fiduciary Trust Co. 11.27 %	1,18,10,729	11.27 %	240 M $
AQR Capital Management LLC 7.735 %	81,04,869	7.735 %	165 M $
STATE STREET CORPORATION 6.298 %	65,99,441	6.298 %	134 M $
Richard Barry 3.07 %	32,16,667	3.07 %	65 M $
Erste Asset Management GmbH 2.604 %	27,28,945	2.604 %	56 M $
abrdn, Inc. 2.149 %	22,51,593	2.149 %	46 M $
Two Sigma Investments LP 2.04 %	21,37,764	2.04 %	43 M $
UBS Financial Services, Inc. 1.952 %	20,45,037	1.952 %	42 M $
D.E. Shaw & Co., Inc. 1.915 %	20,07,025	1.915 %	41 M $
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	81.29%
Other	9.2%
State Street Corp.	6.3%
Individuals	5.22%
Clear Street Group, Inc.	0.41%
Schweizerische Nationalbank	0.19%
SEI Investments Co.	0.09%
ING Groep NV	0.08%
Governments	0.08%
Manulife Financial Corp.	0.02%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	84.85%
Individuals	5.22%
United Kingdom	2.91%
Austria	2.65%
Canada	2.64%
Czech Republic	1.56%
France	0.76%
Sweden	0.55%
Denmark	0.53%
Norway	0.37%
Switzerland	0.22%
Ireland	0.13%
Netherlands	0.13%
Germany	0.12%
Spain	0.07%
Australia	0.06%
China	0.03%
Singapore	0.02%
Belgium	0.02%
Luxembourg	0.02%
Japan	0.01%
Portugal	0.01%

Based on 1000 largest holdings

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. It has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes approximately 40 programs at various stages of discovery, pre-clinical and clinical development.

Employees

1,372

Sector

Pharmaceuticals

Calendar

26/02 - Q4 2025 Earnings Release

More about the company